Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
160 participants
INTERVENTIONAL
2021-12-12
2030-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Data collected will include survival status, cardiac function status, quality of life, laboratory parameters and adverse events. The primary endpoint are the composite of survival at 6 months and, separately, at 24 months, defined as survival with device support, bridge to heart transplant and device explantation due to cardiac recovery, without disabling stroke (mRS \> 3) or device replacement. Data collection will adhere to the follow-up schedule specified in the protocol.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Application of Right Atrial Left Ventricular Fusion Pacing in Patients With CRT Indications
NCT03071978
Corrected Left Ventricular Electrical Delay Predicting Response to Cardiac Resynchronization Therapy
NCT02493907
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
NCT07069738
Evaluation of Left Ventricular AutoThreshold
NCT00812201
Triple-site Biventricular Stimulation in the Optimization of CRT
NCT02350842
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Corheart 6 Left Ventricular Assist System
Subjects with advanced left heart failure despite receiving optimal medical therapy, as per current heart failure management guidelines
Corheart 6 left ventricular assist system
Corheart 6 left ventricular assist system provides circulatory support for patients with advanced left heart failure.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Corheart 6 left ventricular assist system
Corheart 6 left ventricular assist system provides circulatory support for patients with advanced left heart failure.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject who have undergone Corheart 6 implantation on or after October 1, 2021.
* Body Surface Area (BSA) \> 1.0 m2.
* Women of childbearing potential must use agree to use a effective method of contraception for the duration of the study.
* Diagnosis of NYHA Class IV heart failure, refractory to optimal guideline-directed medical therapy (GDMT) (e.g., ACE inhibitors, β-blockers, and diuretics).
* Left Ventricular Ejection Fraction (LVEF) \< 30%, with at least one of the following conditions:
1. Dependence on an intra-aortic balloon pump (IABP), extracorporeal membrane oxygenation (ECMO), or other short-term mechanical circulatory support with an inability to be weaned.
2. Dependence on continuous intravenous inotropic support.
3. Meets the diagnostic criteria for cardiogenic shock: blood pressure \< 90/60 mmHg, cardiac index \< 2.0, pulmonary capillary wedge pressure \> 18 mmHg
* Subject or their legally authorized representative agrees to participate in the study and signs the informed consent form.
Exclusion Criteria
* Presence of active, uncontrolled infection confirmed through clinical symptoms and laboratory tests.
* Based on the investigator's judgment, presence of technical difficulties that would lead to unacceptable surgical risk.
* Subject is intolerant to anticoagulation or antiplatelet therapy, or cannot receive other perioperative and postoperative treatments deemed necessary by the investigator based on the patient's health condition.
* Require biventricular assist device support.
* Pregnancy.
* Presence of moderate to severe aortic regurgitation or a history of mechanical aortic valve implantation but refuse or is unable to converted to a bioprosthesis or oversewn at the time of LVAD implant.
* History of any organ transplant.
* Presence of unresolved thrombocytopenia or severe coagulopathy, such as disseminated intravascular coagulation (DIC).
* Preoperative total bilirubin (TBIL) \> 3.0 mg/dL, serum creatinine (SCr) \> 3.0 mg/dL, or requirement for dialysis within 48 hours prior to surgery.
* History of severe chronic obstructive pulmonary disease (COPD), restrictive lung disease, or diagnosed primary pulmonary hypertension.
* Presence of pulmonary embolism within 3 weeks prior to enrollment.
* Pulmonary artery systolic pressure greater than 60 mmHg and meet at least one of the criteria which prove the pulmonary vessels is unresponsive to pharmacologic intervention: a. most recent pulmonary vascular resistance (PVR) ≥ 8 Woods; b. transpulmonary pressure \> 20mmHg.
* History of confirmed, untreated abdominal aortic aneurysm (AAA) or thoracic aortic aneurysm (TAA) \> 5 cm in diameter.
* Significant peripheral vascular disease (PVD) accompanied by rest pain or extremity ulceration.
* Mental illness/disorder, irreversible cognitive dysfunction, or psychosocial issues that may prevent the patient from adhering to the study protocol and the management of the implanted left ventricular assist device, or any condition leading to brain death.
* Presence cancer or other diseases that could limit survival to less than 24 months.
* Participation in any other clinical investigation that is likely to confound study results or affect the study.
* Unforeseen circumstances that the investigator determines to be unsuitable for the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China National Center for Cardiovascular Diseases
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fuwai Hospital Chinese Academy of Medical Sciences
Shenzhen, Guangdong, China
the 7Th People'S Hospital of Zhengzhou
Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Wuhan asia heart hospital
Wuhan, Hubei, China
Nanjing First Hospital
Nanjing, Jiangsu, China
the First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China
Fuwai Hospital
Beijing, , China
Zhongshan Hospital Fudan University
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xiangli Zhang
Role: primary
Zhengdong Hua
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-ZX036
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.